REVIEW 1 cited by
Time-Varying Causal Survival Learning
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
Signed reviews
read the original abstract
This work bridges the gap between staggered adoption designs and survival analysis to estimate causal effects in settings with time-varying treatments, addressing a fundamental challenge in medical research exemplified by the Stanford Heart Transplant study. In medical interventions, particularly organ transplantation, the timing of treatment varies significantly across patients due to factors such as donor availability and patient readiness, introducing potential bias in treatment effect estimation if not properly accounted for. We identify conditions under which staggered adoption assumptions can justify the use of survival analysis techniques for causal inference with time-varying treatments. By establishing this connection, we enable the use of existing survival analysis methods while maintaining causal interpretability. Furthermore, we enhance estimation performance by incorporating double machine learning methods, improving efficiency when handling complex relationships between patient characteristics and survival outcomes. Through both simulation studies and application to heart transplant data, our approach demonstrates superior performance compared to traditional methods, reducing bias and offering theoretical guarantees for improved efficiency in survival analysis settings.
Forward citations
Cited by 1 Pith paper
-
CAST: Time-Varying Treatment Effects with Application to Chemotherapy and Radiotherapy on Head and Neck Squamous Cell Carcinoma
CAST fits quadratic and spline curves through ten horizon-specific causal forest estimates, reporting a chemotherapy survival benefit in 2,651 head and neck cancer patients that peaks between 50 and 65 months and then...
Discussion (0). Continue with ORCID to comment.